Cullinan Therapeutics Inc.
Clinical trials sponsored by Cullinan Therapeutics Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody takes on Hard-to-Treat myeloma Results expected Sep 2026 (estimated)
- New lupus drug CLN-978 enters early human testing Results expected Dec 2026 (estimated)
- New drug CLN-049 aims to fight Hard-to-Treat blood cancers Results expected Jan 2027 (estimated)
-
New drug targets rare lung cancer mutation
Disease control OngoingThis study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.
Phase 1/2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug CLN-619 enters human trials for advanced tumors
Disease control OngoingThis early-stage trial tests a new drug called CLN-619, which targets specific proteins on cancer cells to help the immune system fight tumors. It is being tested alone or with another drug (pembrolizumab) in about 440 adults with advanced solid tumors that have spread. The main …
Phase 1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New antibody takes on Hard-to-Treat myeloma
Disease control OngoingThis early-stage trial is testing a drug called CLN-619 in 30 people with multiple myeloma that has come back or stopped responding to treatment. CLN-619 is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug …
Phase 1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC